Pathways

PathWhiz ID Pathway Meta Data

PW124564

Pw124564 View Pathway
metabolic

Para-cresol

Homo sapiens

PW124551

Pw124551 View Pathway
drug action

Ximelagatran Mechanism of Action Action Pathway

Homo sapiens
Ximelagatran is an anti-coagulant thrombin inhibitor that binds reversibly to the catalytic site and anion-binding exosite inhibiting the cleavage of fibrinogen into fibrin. Ximelagatran is used to treat heparin-induced thrombocytopenia as well as to prevent thrombosis. It is used in patients that are undergoing percutaneous coronary intervention or who have a risk in acute coronary syndromes caused by unstable angina or non-ST segment elevation. Thrombin is an important proteinase as it cleaves fibrinogen into fibrin monomers which help form the thrombus that forms the clot at the site of vascular injury. Because ximelagatran inhibits thrombin, clotting cannot form which is ideal for heart surgeries and some heart conditions. Ximelagatran should be monitored as it inhibits clotting so other injuries won't clot and it also can cause blood stagnation. Monitoring changes in hematocrit and blood pressure is extremely important when taking this drug. It is normally administered intravenously so that it is delivered to the site of action right away and can be controlled more easily. Ximelagatran is an anticoagulant drug used to prevent and treat blood clots, and was the first drug in the anticoagulant drug class to be able to be ingested orally. It was discontinued from distribution by its parent company AstraZeneca in 2006 as it was found to raise liver enzyme levels in patients and cause liver damage as a result.

PW124550

Pw124550 View Pathway
drug action

Argatroban Mechanism of Action Action Pathway

Homo sapiens
Argatroban is a selective thrombin inhibitor that binds reversibly to the catalytic site and anion-binding exosite inhibiting the cleavage of fibrinogen into fibrin. Unlike bivalirudin, argatroban is not a synthetic peptide but a derivative of L-arginine. Argatroban is used to treat heparin-induced thrombocytopenia as well as to prevent thrombosis. It is used in patients that are undergoing percutaneous coronary intervention or who have a risk in acute coronary syndromes caused by unstable angina or non-ST segment elevation. Thrombin is an important proteinase as it cleaves fibrinogen into fibrin monomers which help form the thrombus that forms the clot at the site of vascular injury. Because Argatroban inhibits thrombin, clotting cannot form which is ideal for heart surgeries and some heart conditions. Argatroban should be monitored as it inhibits clotting so other injuries won't clot and it also can cause blood stagnation. Monitoring changes in hematocrit and blood pressure is extremely important when taking this drug. It is normally administered intravenously so that it is delivered to the site of action right away and can be controlled more easily.

PW124549

Pw124549 View Pathway
drug action

Lepirudin Mechanism of Action Action Pathway

Homo sapiens
Lepirudin is a synthetic peptide thrombin inhibitor that binds reversibly to the catalytic site and anion-binding exosite inhibiting the cleavage of fibrinogen into fibrin. Lepirudin is used to treat heparin-induced thrombocytopenia as well as to prevent thrombosis. It is used in patients that are undergoing percutaneous coronary intervention or who have a risk in acute coronary syndromes caused by unstable angina or non-ST segment elevation. Thrombin is an important proteinase as it cleaves fibrinogen into fibrin monomers which help form the thrombus that forms the clot at the site of vascular injury. Because Lepirudin inhibits thrombin, clotting cannot form which is ideal for heart surgeries and some heart conditions. Lepirudin should be monitored as it inhibits clotting so other injuries won't clot and it also can cause blood stagnation. Monitoring changes in hematocrit and blood pressure is extremely important when taking this drug. It is normally administered intravenously so that it is delivered to the site of action right away and can be controlled more easily. Production of lepirudin by Bayer Pharmaceuticals has been stopped in 2012.

PW124541

Pw124541 View Pathway
metabolic

Phosphatidylcholine metabolism

Homo sapiens

PW124533

Pw124533 View Pathway
metabolic

Drug Metabolism Template

Homo sapiens

PW124525

Pw124525 View Pathway
drug action

Doxycycline

Homo sapiens

PW124523

Pw124523 View Pathway
drug action

Minocycline

Homo sapiens

PW124513

Pw124513 View Pathway
drug action

Dasatinib Inhibition of BCR-ABL (New)

Homo sapiens
Dasatinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the blood and acute lymphoblastic leukemia . The cause of CML pathophysiology is the BCR-ABL fusion protein - the result of a genetic abnormality known as the Philadelphia chromosome in which Abelson Murine Leukemia viral oncogene homolog 1 (ABL1) translocates within the Breakpoint Cluster Region (BCR) gene on chromosome 22. BCR-ABL is a cytoplasm-targeted constitutively active tyrosine kinase that activates several oncogenic pathways which promote increased cell proliferation and survival including the MAPK/ERK Pathway, the JAK-STAT Pathway, and the PI3K/Akt pathway. For greater detail, refer to the pathway titled BCR-ABL Action in CML Pathogenesis. Dasatinib is able to bind ABL with greater affinity than Imatinib (25-55 times more potent). It is therefore administered to patients with Imatinib resistance.

PW124512

Pw124512 View Pathway
signaling

Jasmonic Acid Biosynthesis 1612785177

Arabidopsis thaliana